Video

Dr. Gupta on the role of immunotherapy as future standard of care for MIBC

Author(s):

Urology Times staff

“I think the audience would be encouraged to know that in the future, it seems like immunotherapy would become the standard of care,” says Shilpa Gupta, MD.

In this video, Shilpa Gupta, MD, discusses the future research and takeaways associated with the study, “Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gupta is the director of genitourinary oncology at Cleveland Clinic in Ohio.

Related Videos
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Related Content
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
April 29th 2025

Cxbladder Triage may help patients avoid unnecessary cystoscopies

Benjamin P. Saylor
The study population was able to avoid 952 cystoscopies and 71 CT scans, according to the investigators.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Sandip M. Prasad, MD, MPhil
April 27th 2025

UGN-102 positions itself as an alternative to TURBT for low-grade NMIBC

Benjamin P. Saylor
"I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Mark D. Tyson II, MD, MPH
April 27th 2025

Cretostimogene yields high CR rate in BCG-unresponsive NMIBC

Benjamin P. Saylor
"97% [of patients] remain progression free, and 84.5% avoided cystectomy, highlighting cretostimogene’s bladder-sparing potential,” said Mark D. Tyson II, MD, MPH.
Neal D. Shore, MD, FACS
April 26th 2025

CREST: Significant EFS boost seen with sasanlimab plus BCG in NMIBC

Benjamin P. Saylor
“In the patients with CIS, the probability of a continued complete response at 36 months was 92% vs 67.7%," said Neal D. Shore, MD, FACS.
© 2025 MJH Life Sciences

All rights reserved.